Related Experiment Video
Updated: Jun 19, 2026
13:27
Generation of Human CD40-activated B cells
Published on: October 16, 2009
Generation of human CD40-activated B cells.
Tanja M Liebig1, Anne Fiedler, Shahram Zoghi
1Laboratory for Tumor and Transplantation Immunology and Stem Cell Transplantation Program, University Hospital of Cologne, Department I of Internal Medicine.
Journal of Visualized Experiments : Jove
|October 20, 2009
Summary
CD40-activated B cells (CD40-B cells) are effective antigen-presenting cells (APCs) for cancer immunotherapy, offering advantages over dendritic cells (DCs). These cells can be generated in large quantities from small blood samples and efficiently prime T cells for therapeutic vaccination.
Area of Science:
- Immunology
- Cell Biology
- Cancer Research
Background:
- CD40-activated B cells (CD40-B cells) are emerging as a potent alternative to dendritic cells (DCs) as antigen-presenting cells (APCs) in cancer immunotherapy.
- Unlike DCs, CD40-B cells express a complete set of homing molecules for secondary lymphoid organs, enhancing their migratory capacity.
Purpose of the Study:
- To detail a protocol for generating fully activated CD40-B cells from human peripheral blood mononuclear cells (PBMCs).
- To highlight the potential of CD40-B cells as a tool for cancer immunotherapy and vaccination.
Main Methods:
- Activation of B cells using CD40 ligand, interleukin-4 (IL-4), and cyclosporin A (CsA).
- Expansion of CD40-B cells in vitro using NIH/3T3 cells expressing recombinant human CD40 ligand (tCD40L NIH/3T3).
- Culture cycle involves replenishing key molecules every 3-4 days, with regular checks for CD40 ligand expression on transfectants.
Main Results:
- Protocol yields highly pure (>95%) CD40-B cells within 14 days.
- CD40-B cells can be expanded for over 65 days without functional loss.
- These cells efficiently present antigens to T cells, priming naive and expanding memory T cells.
Conclusions:
- CD40-B cells are a viable and scalable source of immuno-stimulatory APCs for cancer immunotherapy.
- CD40-B cells offer a promising platform for therapeutic and preventive cancer vaccination strategies.
Related Concept Videos
01:22T Cell Activation and Clonal Selection
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
01:24B Cell Activation and Differentiation
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...